a Blue chip investor and micro cap trader.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
THE BIG FADE, AGAIN?
Collector Biosciences has broken the wide and weak rising the short-term trend up and an even stronger rising rate is indicated. For any reaction back there will now be support on the roof on the current trend broken at $1.82, a level that may pose a second chance to hit a runner. According to fan-theory $2.13 will be the next possible trend-top level and thereby pose a resistance level which may not be broken at the first attempt.
Bird: ROFLMAO $1.90's after hours,
Free market manipulation, I'm sure....;)
The US Constitution's from 1789,
but it still works as guidance like CLRB's corporate slide show. 9-8-16
Better than nothing!
Anyone with a timeline updated in 2017 is free to post it for the common good.
Investors are betting on a cancer cure with these stocks:
From today's CNBC:
https://www.cnbc.com/2017/08/31/investors-are-betting-on-a-cancer-cure-with-these-stocks.html
Eagle's Sassouni pointed out that since the big drug companies are losing billions of dollars every year to generic versions and have little to spend on their own research and development, they are looking to buy smaller biotechnology companies that are developing their own products.
HERE IS THE DEAL ON CLRB:
(See timeline on page 10- we are close!):
http://cellectar.com/wp-content/uploads/2015/05/CLRB-Corporate-Presentation-9.8.16.pdf
Sure I can compare them,
And you can contrast them too.
The point is that once a micropharma proves itself in a high liquidity low interest rate environment, it WILL BE acquired and CLRB will laugh all the way to the bank...no matter what common stock share holders think.
https://www.thestreet.com/story/14201217/1/global-blood-shares-pop-on-priority-designation-kite-pharma-rises-on-patent-news-biotech-movers.html
Gee wizz CLRB IS AT $1.74 already...swoon time?
My close target today: $1.75
A modest proposal...
"Pays your money and takes your chances" (after DD, of course)!
Or possible clinical depression
On sugar spike high and gloomy CLRB forward looking forecast.
YOU ARE WHAT YOU EAT,
BIG BUYOUT NEWS!!!
This is what going to happen to CLRB:
https://www.cnbc.com/2017/08/28/gilead-to-buy-kite-pharma-for-about-11-billion-in-cash-dow-jones.html
Today's close could be promising,
and a validation of the last press release.
HAS THE MARKET TREND CHANGED FOR CLRB FROM DEAD MONEY
TO GROWTH?
CLRB STOCK IS DOMINATED BY TRADERS,
AKA, "FLIPPERS". IT SWOONS AFTER PRESS RELEASES, EVEN SUBSTANTIVE ONES LIKE A FEW DAYS AGO.
CLRB WILL DISAPPOINT UNTIL IT IS DOMINATED BY LONG TERM INVESTORS- IF THERE IS ANY SUCH THING ANYMORE.
I HAVE A SCHEDULE FOR PROJECTED CLINICAL TRIAL UPDATES THAT PROVIDES A TIMELINE FOR ALL THAT MATTERS FOR CLRB:
SCIENTIFIC AND VERIFIED RESULTS FOR CLRB TECHNOLOGY,
I intend on buying before clinical trial news and SELLING THE NEWS IF IT IS ANYTHING BUT GRAND SLAM NEWS THAT WILL INDUCE A BUYOUT.
Until then, I will keep on bashing this POS.
LOL
BTW: looks like CLRB WILL CLOSE TODAY WITH A 62.8% retracement on the losses of yesterday. INTERESTING! http://www.investopedia.com/terms/f/fibonacciretracement.asp
Today's close was only relatively positive,
So will be watching tomorrow's close to see if yesterday's PR has made a real sentiment difference- brought "deep pocket" buyers into this company/stock.
Cheers!
Typical price action after "fluff" news induced rally,
Let's see where CLRB CLOSES today- VERY IMPORTANT INDICATOR OF ANY MARKET SENTIMENT CHANGE ABOUT CLRB'S FUTURE PRICE TREND!
In other words, WAS THE PR FLUFF NEWS OR NOT?
The close today and tomorrow should answer the question!
I have been buying CLRBZ warrants today
to leverage my money and save $1 per warrant over the cost of a CLRB common share. CLRBZ has much better alpha than CLRBW warrants which are even cheaper.
$3.00-land the week after?
A Phase2 CLR131 clinical trial update will put CLRB THERE OR HIGHER FROM WHAT I hear.
This stock is a hold (and a buy) from what I read.
Today's PR is a game changer!
ESPECIALLY THIS PART:
"...Utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the company’s PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells.
Looks like CLRB $2.00-land this week,
Because the big buyers are squeezing the shorts until it hurts too much, you know where!
Thomson Reuters/Verus upgrades CLRB TO HOLD from SELL
BY Investars Analyst Actions - public
— 4:21 PM ET 08/21/2017
On August 21, 2017 Thomson Reuters/Verus upgraded CELLECTAR BIOSCIENCES INC (CLRB) from SELL to HOLD.
Make that $1.64 pps on well over 200,000 shares traded.
$1.59 pps now...
AND this part too:
[color=red]"...To date, the company’s research has demonstrated that the conjugated molecules are inactive until cleavage of the payload from the phospholipid ether. This mechanism provides significant opportunity to reduce the off-target impact and associated side effects of many chemotherapeutics. These data show greater than 500-fold dilution separation between effects in tumor cells and effects in normal cells, and that this separation can be controlled by the linker chemistry. Importantly, the company has also been able to show that its novel linker chemistry allows for the payload to be selectively cleaved within the tumor cells, resulting in significant potency..."
Yes, AO, and I like this section:
"...MADISON, Wis., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that its Phospholipid Drug Conjugate research program has generated numerous PDC molecules that show significant improved pharmacologic activity versus the payload molecule alone.
Utilizing a selection of novel linkers to attach proprietary cytotoxic molecules to the company’s PDC platform, Cellectar has formulated new compounds specifically designed for improved tumor targeting and fewer off-target adverse effects. The research has demonstrated that with a variety of payloads, the phospholipid ether molecules provide, on average, a greater than 20-fold increase in delivery of the PDC to cancerous cells...."
Thanks, AO.
CLRB UP 5.44% on
208,049 Shares traded in day session. I think the shorts are starting to worry about the trend.
But tomorrow is another day to watch to see if the trend is up or headed for the gap at $1.38 pps?
Up 9.8 % after hours on this News?
http://ih.advfn.com/p.php?pid=nmona&article=75446576&symbol=CLRB
Is the TREND our friend if we are long CLRB?
Recent CNBC News Mentioning CLRB:
https://www.cnbc.com/2017/08/09/pr-newswire-latest-rd-success-fda-approvals-and-significant-advances-in-clinical-trials-boosting-biotech-sector.html
"...Collector Biosciences Inc. (NASDAQ: CLRB) came to a close up 11.39% on Tuesday at $1.76 with a volume of over 5.9 million shares traded by the market close. The company recently announced its lead PDC compound, CLR 131 has achieved a median overall survival of 22.5 months to date after a single dose infusion of 12.5 mCi/m2 in patients with multiple myeloma. Patients in the first cohort of the company's Phase 1 clinical trial had an average of 5.8 prior lines of treatment and therefore were considered to be heavily pretreated. It is important to note that the trial remains ongoing, and the overall survival could continue to increase over time. While there have been no head-to-head studies, for comparison, this ongoing overall survival length from the company's Phase 1 clinical trial exceeds historic published outcomes of currently marketed second and third line treatment modalities for multiple myeloma...."
BUY THE DIP!
CLRB : Cellectar Bio's lead candidate CLR 131 achieves median OS of 22.5 months after single infusion in multiple myeloma patients; shares ahead 28% premarket
MY TARGET: $6.50
LONG wait coming to an end
In coming months: Target: $7.50 pps
Clrb LONGS being REWARDED
Well, today is starting up on the bright side,
With 25,000 shares bought early today.
And CLRB 's price action today is much better than yesterday.
No controversy about the open today.
Get out the Pom-poms. ..$1.65...no wait there was a sale, a small one, taking price back down.
Sunofwolf, are you selling again ...$1.54....dizzy and Pom-poems away...boo-who...
Starting to hear that too!
+ 17%
Short squeeze in progress?
Right...no new filings?
There will be after a new filing on clinical trials news!
What's up .
Besides today's 14% gain....is this sunofwolf' big turn? Newson clinical trials coming soon?
So many leaks in DC and Wallstreet!!!
Nice close yesterday; nice open today?
WHAT's UP WITH THIS STOCK? I was beginning to think it was dead money!...after no CT news around July 1st.
WHAT's UP with this stock?
$1.42 was the bottom?
Climax selling in first two hours today...
No, gap was filled today.
CT update is due!